Zobrazeno 1 - 10
of 620
pro vyhledávání: '"Lisa A. Carey"'
Autor:
Daniel G. Stover, Roberto Salgado, Oleksander Savenkov, Karla Ballman, Erica L. Mayer, Mark Jesus M. Magbanua, Sherene Loi, Mark Vater, Kristyn Glover, Mark Watson, Yujia Wen, W. Fraser Symmans, Charles Perou, Lisa A. Carey, Ann H. Partridge, Hope S. Rugo
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-5 (2024)
Abstract Association of stromal tumor-infiltrating lymphocytes (sTILs) with survival outcomes among patients with metastatic breast cancer (MBC) remains unclear. The primary objective was to evaluate the association of sTILs with progression-free sur
Externí odkaz:
https://doaj.org/article/83a9a621c06f4389a3a50e11d37a5714
Autor:
Fatima Cardoso, Shani Paluch-Shimon, Eva Schumacher-Wulf, Leonor Matos, Karen Gelmon, Matti S. Aapro, Jyoti Bajpai, Carlos H. Barrios, Jonas Bergh, Elizabeth Bergsten-Nordström, Laura Biganzoli, Maria João Cardoso, Lisa A. Carey, Mariana Chavez-MacGregor, Runcie Chidebe, Javier Cortés, Giuseppe Curigliano, Rebecca A. Dent, Nagi S. El Saghir, Alexandru Eniu, Lesley Fallowfield, Prudence A. Francis, Sandra X. Franco Millan, Jenny Gilchrist, Joseph Gligorov, William J. Gradishar, Renate Haidinger, Nadia Harbeck, Xichun Hu, Ranjit Kaur, Belinda Kiely, Sung-Bae Kim, Smruti Koppikar, Marion J.J. Kuper-Hommel, Frédéric E. Lecouvet, Ginny Mason, Shirley A. Mertz, Volkmar Mueller, Claire Myerson, Silvia Neciosup, Birgitte V. Offersen, Shinji Ohno, Olivia Pagani, Ann H. Partridge, Frédérique Penault-Llorca, Aleix Prat, Hope S. Rugo, Elzbieta Senkus, George W. Sledge, Sandra M. Swain, Christoph Thomssen, Daniel A. Vorobiof, Peter Vuylsteke, Theresa Wiseman, Binghe Xu, Alberto Costa, Larry Norton, Eric P. Winer
Publikováno v:
Breast, Vol 76, Iss , Pp 103756- (2024)
This manuscript describes the Advanced Breast Cancer (ABC) international consensus guidelines updated at the last two ABC international consensus conferences (ABC 6 in 2021, virtual, and ABC 7 in 2023, in Lisbon, Portugal), organized by the ABC Globa
Externí odkaz:
https://doaj.org/article/de357938368a491d8c29ea9020d3b42e
Autor:
Sara A. Hurvitz, Aditya Bardia, Kevin Punie, Kevin Kalinsky, Lisa A. Carey, Hope S. Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M. Tolaney
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-11 (2024)
Abstract In this post hoc analysis of the ASCENT study, we compared outcomes with sacituzumab govitecan (SG) vs single-agent chemotherapy in clinically important subgroups of patients with metastatic triple-negative breast cancer (mTNBC). Patients wi
Externí odkaz:
https://doaj.org/article/57d3700a66394fa696463144047acd65
Autor:
Alina M. Hamilton, Andrea Walens, Sarah C. Van Alsten, Linnea T. Olsson, Joseph Nsonwu-Farley, Xiaohua Gao, Erin L. Kirk, Charles M. Perou, Lisa A. Carey, Melissa A. Troester, Yara Abdou
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-11 (2024)
Abstract Purpose Survivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5 has not been well studied among racially diverse populations where aggressive breas
Externí odkaz:
https://doaj.org/article/27b60ce2e45d4cbb9f8f5a40b8cba4bf
Autor:
Mattia Rediti, Aranzazu Fernandez-Martinez, David Venet, Françoise Rothé, Katherine A. Hoadley, Joel S. Parker, Baljit Singh, Jordan D. Campbell, Karla V. Ballman, David W. Hillman, Eric P. Winer, Sarra El-Abed, Martine Piccart, Serena Di Cosimo, William Fraser Symmans, Ian E. Krop, Roberto Salgado, Sherene Loi, Lajos Pusztai, Charles M. Perou, Lisa A. Carey, Christos Sotiriou
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-18 (2023)
Abstract The identification of prognostic markers in patients receiving neoadjuvant therapy is crucial for treatment optimization in HER2-positive breast cancer, with the immune microenvironment being a key factor. Here, we investigate the complexity
Externí odkaz:
https://doaj.org/article/14a09996519f49368d11a06978543f0a
Autor:
Sara A. Hurvitz, Aditya Bardia, Kevin Punie, Kevin Kalinsky, Lisa A. Carey, Hope S. Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M. Tolaney
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/b7e0ce4edf704cddba47c313492804ed
Autor:
Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Diéras, Lisa A. Carey, Luca Gianni, Martine J. Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Kevin Kalinsky
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/abb00ee86ac244e6959147aeb2f4a725
Autor:
Tal Sella, Yue Zheng, Shoshana M. Rosenberg, Kathryn J. Ruddy, Shari I. Gelber, Rulla M. Tamimi, Jeffrey M. Peppercorn, Lidia Schapira, Virginia F. Borges, Steven E. Come, Lisa A. Carey, Eric P. Winer, Ann H. Partridge
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract Extended adjuvant endocrine therapy (eET) improves outcomes in breast cancer survivors. Most studies however have been limited to postmenopausal women, and optimal eET for young survivors is uncertain. We report eET use among participants in
Externí odkaz:
https://doaj.org/article/d8f59f34132643f3837f4026790bf189
Autor:
Zev M. Nakamura, Allison M. Deal, Eliza M. Park, Kate E. Stanton, Yesy E. Lopez, Laura J. Quillen, Erin O’Hare Kelly, Hillary M. Heiling, Kirsten A. Nyrop, Emily M. Ray, E. Claire Dees, Katherine E. Reeder‐Hayes, Trevor A. Jolly, Lisa A. Carey, Yara Abdou, Oludamilola A. Olajide, Julia K. Rauch, Ranjit Joseph, Anureet Copeland, Megan A. McNamara, Tim A. Ahles, Hyman B. Muss
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 8172-8183 (2023)
Abstract Background Cognitive difficulties have been described after chemotherapy for breast cancer, but there is no standard of care to improve cognitive outcomes in these patients. This trial examined the feasibility, tolerability, acceptability, a
Externí odkaz:
https://doaj.org/article/d2562d0fa30245228e0ed1a363d25b5d
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract The development of immunotherapy agents has revolutionized the field of oncology. The only FDA-approved immunotherapeutic approach in breast cancer consists of immune checkpoint inhibitors, yet several novel immune-modulatory strategies are
Externí odkaz:
https://doaj.org/article/dbf26895bdc04849b022584f378e24e0